Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia

Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1986-10, Vol.18 (4), p.521-529
Main Authors: YANGCO, B. G, PALUMBO, J. A, NOLEN, T, LIFLAND, P. W, SCHLEUPNER, C. J
Format: Article
Language:English
Subjects:
Adult
Aged
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteria - drug effects
Biological and medical sciences
Cefamandole - adverse effects
Cefamandole - pharmacology
Cefamandole - therapeutic use
Ceftazidime - adverse effects
Ceftazidime - pharmacology
Ceftazidime - therapeutic use
Humans
Medical sciences
Microbial Sensitivity Tests
Middle Aged
Pharmacology. Drug treatments
Pneumonia - drug therapy
Pneumonia - etiology
Pneumonia - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftazidime and cefamandole were compared in a randomized multicentre trial in hospitalized patients with pneumonia. Of 290 patients enrolled, 92 patients in the ceftazidime group and 71 patients in the cefamandole group were evaluable. Geometric mean MICs of organisms isolated and tested to ceftazidime were within achievable therapeutic serum concentrations of ceftazidime. Satisfactory clinical responses were observed in 91% (84/92) of ceftazidime-treated patients and 83% (59/71) of cefamandole-treated patients (P greater than 0.05). Superinfection occurred in one (1%) ceftazidime-treated patient and in five (7%) cefamandole-treated patients. Side effects were infrequent with either treatment. Ceftazidime is as safe and effective as cefamandole for the treatment of pneumonia due to a variety of Gram-positive and Gram-negative pathogens.
ISSN:0305-7453
1460-2091